SR-18292

CAS No. 2095432-55-4

SR-18292( SR-18292 | SR 18292 | SR18292 )

Catalog No. M17428 CAS No. 2095432-55-4

SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 31 In Stock
5MG 50 In Stock
10MG 80 In Stock
25MG 170 In Stock
50MG 267 In Stock
100MG 425 In Stock
500MG 888 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SR-18292
  • Note
    Research use only, not for human use.
  • Brief Description
    SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.
  • Description
    SR-18292 is a PGC-1α inhibitor. SR-18292 reduces blood glucose, strongly increases hepatic insulin sensitivity, and improves glucose homeostasis in dietary and genetic mouse models of T2D.
  • In Vitro
    The transcriptional coactivator PGC-1α plays a pivotal role in energy homeostasis by co-activating transcription factors that regulate fat and glucose metabolism. SR-18292 increases the interaction of PGC-1α with the acetyl transferase GCN5 and reduces co-activation of nuclear hormone receptor HNF4α by PGC-1α. SR-18292 suppresses HNF4α/PGC-1α gluconeogenic transcriptional function. By increasing the interaction of GCN5 with PGC-1α, SR-18292 increases the acetylation of specific PGC-1α lysine residues that might subsequently decrease its gluconeogenic activity.
  • In Vivo
    SR-18292 reduces fasting blood glucose, increases hepatic insulin sensitivity and improves glucose homeostasis in diabetic mice. The high fat diet (HFD) fed mice, a dietary model of obesity and T2D, are treated with SR-18292 (45mg/kg) via I.P. injection for 3 consecutive days and again on day 4 before measuring fasting blood glucose. Strikingly, mice that are treated with SR-18292 have significantly lower levels of fasting blood glucose concentrations compared to matched vehicle-treated control mice. The induction of gluconeogenic gene expression is a regulatory component of the response to fasting. Importantly, gluconeogenic gene expression, specifically that of Pck1, is inhibited in livers isolated from mice treated with SR-18292.
  • Synonyms
    SR-18292 | SR 18292 | SR18292
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    PGC-1α
  • Research Area
    Metabolic Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    2095432-55-4
  • Formula Weight
    366.51
  • Molecular Formula
    C23H30N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 100 mg/mL; 272.85 mM
  • SMILES
    CC(C)(C)N(Cc1ccc(C)cc1)CC(O)COc3cccc2nccc23
  • Chemical Name
    1-((1H-indol-4-yl)oxy)-3-(tert-butyl(4-methylbenzyl)amino)propan-2-ol

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Sharabi K,etal.Selective Chemical Inhibition of PGC-1α Gluconeogenic Activity Ameliorates Type 2 Diabetes.Cell. 2017 Mar 23;169(1):148-160.
molnova catalog
related products
  • BRD9757

    BRD9757 is a potent, selective HDAC6 inhibitor with IC50 of 8 nM.

  • SALL4 peptide FFW

    SALL4 peptide FFW (RRKFAKFQWI, FFW peptide) is a potent therapeutic SALL4 peptide antagonist of SALL4-NURD.

  • LAQ824

    LAQ824 (Dacinostat) is a novel HDAC inhibitor with IC50 of 32 nM and is known to activate the p21 promoter.